Biochemical effects of irbesartan in experimental diabetic nephropathy

Indian Journal of Pharmacology

Volumn 41, Issue 6, 2009, Pages 252-254

  Vaishya, Richa ^a   Singh, J ^a   Lal, Harbans ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diabetic nephropathy; Irbesartan; Streptozotocin

Indexed keywords

CREATININE; GLUCOSE; INSULIN; IRBESARTAN; POTASSIUM ION; PROTEIN; SODIUM ION; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; NONHUMAN; POLYURIA; POTASSIUM EXCRETION; PREMEDICATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SODIUM URINE LEVEL; STREPTOZOCIN DIABETES; UREA BLOOD LEVEL; URINE VOLUME;

EID: 77949445463     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.59922     Document Type: Article

References (18)

1. Jenkins DA, Cowan P, Coolier A, Watson ML, Clarke BF. Blood glucose control determines the renal hemodynamic response to angistensin converting enzyme inhibition in type I diabetes. Diabetic Med 1990; 7:252-257
2. Thomas PK. Diabetic neuropathy, human and experimental. Drugs 1986; 32:36-42.
3. Friedman EA. Diabetic Nephropathy: Strategy for therapy. In: Friedman EA, Charles M, Paterson, editors. Boston: Martins Nijhoff; 1985. p. 1-229.
4. Varun SN, Arun K. Reno protection with angiotensin type I receptor blockers in hypertension. Indian heart J 2000; 52:89-92.
5. Krolewski AS, Warran JH, Christlieb AR. Hypercholesterolaemia - A determinant of renal function loss and deaths in IDDM and nephropathy. Kidney Int 1994; 45:S125-31.
6. Gustav GB, Raunhild B, Susan K, Christian M, Ernst M. Time course and extent of angiotensin II antagonism after irbesatran, losartan and vatsartan in humans assessed by angiotensin II dose response and radioligant and receptor assay. Clin Pharmacol Ther 1999; 66:367-373
7. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6:24-27
8. Johnson MA, Rohlfs EM, Silverman LM. Determination of protein in urine. In: Burtis CA, Ashwood ER, Editors. Teitz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders 1999. p. 525-526
9. Marsh WH, Fingerhut B, Miller H. Automated and manual direct methods for the determination of blood urea. Clin Chem 1965;11:624-627
10. Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood ER, editors. Teitz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders; 1999. p. 1204-1210
11. Tanya MO, Yunzia YU, Siama P, Steven P, Zafi ra K, Rober NP et al... Prevention of albuminuria by aminoguanidine or ramipril in Streptozotocin -induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000;49:87-93.
12. Papaccio G, Chieffi BG, Mezzogiorno V, Esposito V. Extra islet infi ltration in NOD mouse: observations after immunomodulation. Pancreas 1993; 8:459-464
13. Parving HH, Lehnert H, Brochnr-Mortensh J, Gomis R, Anderson S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type2 diabetes. N Engl J Med 2001; 345:870-878
14. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D' Ambrossio R et al... Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo controlled crossover study. Diabetes Care 2002; 25:1909-1913
15. Ziai F, Ots M, Provoost AP, Troy JL, Reenke HG, Brenner BM et al... The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50:S132-36.
16. Cooper ME. Interaction of metabolic and hemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44:1957-1962
17. Davis BJ, Cao Z, Gasparo MD, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonist and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. J Hypertens 2003; 21:209-216
18. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S. Angiotensin II type 2 receptor over expression activates the vascular kinin system and causes vasodilatation. J Clin Invest 1999; 104:925-935